A phase I study of Aventis Pasteur live recombinant ALVAC-HIV (vCP205, HIV-1 Env/Gag/Pol) in seronegative adults administered (1) subcutaneously via ex vivo transfected, autologous dendritic cells, (2) intradermally, or (3) intramuscularly

Trial Profile

A phase I study of Aventis Pasteur live recombinant ALVAC-HIV (vCP205, HIV-1 Env/Gag/Pol) in seronegative adults administered (1) subcutaneously via ex vivo transfected, autologous dendritic cells, (2) intradermally, or (3) intramuscularly

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2006

At a glance

  • Drugs HIV vaccine vCP205 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top